Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Verisign Announces the Retirement of George E. Kilguss III, Executive Vice President and Chief Financial Officer
Verisign Announces the Retirement of George E. Kilguss III, Executive Vice President and Chief Financial Officer


VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that after 13 years with the Company, George E. Kilguss III

Verisign Announces the Retirement of George E. Kilguss III, Executive Vice President and Chief Financial Officer
Verisign Announces the Retirement of George E. Kilguss III, Executive Vice President and Chief Financial Officer


VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that after 13 years with the Company, George E. Kilguss III

Humana and Monogram Health Announce Expansion of Comprehensive Kidney Care Program
Humana and Monogram Health Announce Expansion of Comprehensive Kidney Care Program


Humana and Monogram Health are pleased to announce a significant expansion, extending member access to in-home treatment for kidney disease and its underlying causes. Eligible Humana Medicare

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer


Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer


Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI

Form 8.3 - The Vanguard Group, Inc.: Hargreaves Lansdown plc
Form 8.3 - The Vanguard Group, Inc.: Hargreaves Lansdown plc
Form 8.3 - The Vanguard Group, Inc.: Hargreaves Lansdown plc
Walmart To Host Fourth Quarter Earnings Conference Call February 20th, 2025
Walmart To Host Fourth Quarter Earnings Conference Call February 20th, 2025


Walmart Inc. (NYSE: WMT) announced it will hold a live conference call with the investment community at 7 a.m. CST on Thursday, Feb. 20, 2025, to discuss the company's fourth quarter and full-year

Walmart To Host Fourth Quarter Earnings Conference Call February 20th, 2025
Walmart To Host Fourth Quarter Earnings Conference Call February 20th, 2025


Walmart Inc. (NYSE: WMT) announced it will hold a live conference call with the investment community at 7 a.m. CST on Thursday, Feb. 20, 2025, to discuss the company's fourth quarter and full-year

CRH Announces Date for Q4 and Full Year 2024 Results Conference Call
CRH Announces Date for Q4 and Full Year 2024 Results Conference Call


CRH (NYSE: CRH), the leading provider of building materials solutions, will publish its fourth quarter and full year 2024 financial results after the U.S. market closes on Wednesday, February 26

Howmet Aerospace Reports Fourth Quarter and Full Year 2024 Results
Howmet Aerospace Reports Fourth Quarter and Full Year 2024 Results


Howmet Aerospace (NYSE:HWM):



Fourth Quarter 2024 GAAP Financial Results




  • Revenue of $1.9 billion, up 9% year over year, driven by Commercial Aerospace, up 13%


  • Net Income of $314 million

Eaton announces live webcast of investor conference on March 11, 2025
Eaton announces live webcast of investor conference on March 11, 2025


Intelligent power management company Eaton (NYSE:ETN) today announced it will host its 2025 investor conference on Tuesday, March 11, 2025, from 2 p.m. to 5:30 p.m. Eastern time. The purpose of the

Copart, Inc. to Release Second Quarter Fiscal 2025 Results
Copart, Inc. to Release Second Quarter Fiscal 2025 Results


Copart, Inc. (NASDAQ: CPRT) announced today that it will release earnings for the second quarter of fiscal 2025 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 20, 2025.

Copart, Inc. to Release Second Quarter Fiscal 2025 Results
Copart, Inc. to Release Second Quarter Fiscal 2025 Results


Copart, Inc. (NASDAQ: CPRT) announced today that it will release earnings for the second quarter of fiscal 2025 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 20, 2025.

Copart, Inc. to Release Second Quarter Fiscal 2025 Results
Copart, Inc. to Release Second Quarter Fiscal 2025 Results


Copart, Inc. (NASDAQ: CPRT) announced today that it will release earnings for the second quarter of fiscal 2025 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 20, 2025.

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and

Ventas Reports 2024 Full Year Results, Provides 2025 Outlook and Increases Dividend
Ventas Reports 2024 Full Year Results, Provides 2025 Outlook and Increases Dividend


Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today reported results for the full year and fourth quarter ended December 31, 2024.



CEO Remarks



“Ventas delivered strong financial

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in

Philip Morris International to Present at 2025 CAGNY Conference
Philip Morris International to Present at 2025 CAGNY Conference


Regulatory News:



Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast of a presentation by Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau, Chief Financial

Eastman CEO Mark Costa to Address the Barclays Industrial Select Conference
Eastman CEO Mark Costa to Address the Barclays Industrial Select Conference

Eastman Chemical Company (NYSE:EMN):

Industrial Select Conference


Mark Costa, Board Chair and Chief Executive Officer, Eastman Chemical Company (NYSE:EMN), will address the Barclays 42nd

Union Pacific Corporation Executives to Address Barclays 2025 Industrial Select Conference
Union Pacific Corporation Executives to Address Barclays 2025 Industrial Select Conference


Jim Vena, chief executive officer, Jennifer Hamann, executive vice president and chief financial officer, and Kenny Rocker, executive vice president – Marketing & Sales, of Union Pacific

ServiceNow Launches Government Transformation Suite, Uniting High-Impact Solutions Tailored to Administration Priorities
ServiceNow Launches Government Transformation Suite, Uniting High-Impact Solutions Tailored to Administration Priorities


SERVICENOW FEDERAL FORUM ServiceNow (NYSE: NOW), the AI platform for business transformation, today launched the new Government Transformation Suite to increase visibility, accelerate ROI, and

Exelon Reports Fourth Quarter and Full Year 2024 Results and Initiates 2025 Financial Outlook
Exelon Reports Fourth Quarter and Full Year 2024 Results and Initiates 2025 Financial Outlook


Exelon Corporation (Nasdaq: EXC) today reported its financial results for the fourth quarter and full year 2024.



"I am pleased to announce Exelon has delivered against our financial goals for

Exelon Reports Fourth Quarter and Full Year 2024 Results and Initiates 2025 Financial Outlook
Exelon Reports Fourth Quarter and Full Year 2024 Results and Initiates 2025 Financial Outlook


Exelon Corporation (Nasdaq: EXC) today reported its financial results for the fourth quarter and full year 2024.



"I am pleased to announce Exelon has delivered against our financial goals for

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edison International
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edison International


Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edison International (“Edison” or the “Company”) (NYSE: EIX) and reminds investors of the